Document:

EX-10.11

 Exhibit 10.11 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “***”. A COMPLETE VERSION OF THE EXHIBIT HAS BEEN FILED SEPARATELY
WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

SEVENTH AMENDMENT 
 TO 

LICENSE AGREEMENT FOR INTERFERON GAMMA 

This Seventh Amendment To License Agreement for Interferon Gamma (hereinafter “Seventh Amendment”) is entered into effective
December 17, 2013 (the “Seventh Amendment Effective Date”) by and between Genentech, Inc, (“Genentech”) and Vidara Therapeutics International Limited, (“Vidara”), who are now Parties to the License Agreement for
Interferon Gamma dated May 5, 1998, as amended. Genentech and Vidara may each be referred to herein as a “Party” and jointly as the “Parties.” 

RECITALS 
 WHEREAS, on
May 5, 1998, Genentech and Connetics Corporation (hereinafter “Connetics”) entered into the License Agreement for Interferon Gamma. 

WHEREAS, the May 5, 1998 License Agreement for Interferon Gamma was amended by the following: (i) Amendment No. One, dated
December 28, 1998; (ii) Amendment No. Two; dated January 15, 1999; (iii) Amendment No. Three, dated April 27, 1999; (iv) Consent To Assignment Agreement, dated
June 23, 2000; (v) Amendment No. 5, dated January 25, 2001; (vi) Amendment No. 6, dated February 27, 2006; (vii) Fee Agreement Letter dated June 23, 2011; (viii) Consent to Assignment dated
June 23, 2011, (hereinafter collectively “Agreement”), resulting in Genentech and Vidara being the Parties to the Agreement. 

WHEREAS, Genentech and Vidara desire to further amend the Agreement as specified hereinbelow. 

NOW THEREFORE, in consideration for the mutual covenants and conditions set forth below and other valuable consideration, the receipt and
sufficiency of which is hereby acknowledged by the Parties, the Parties make the following Seventh Amendment to the Agreement (hereinafter “Seventh Amendment”) and agree as follows: 

 

	I.	GENERAL 

  

	 	1.	Except as expressly defined herein, all capitalized terms shall have the meanings set forth in the Agreement. 

  

	 	2.	Except as modified and/or amended herein, all of the terms, covenants and conditions contained in the Agreement shall remain unchanged and in full force and effect. In the event of a conflict among the terms and
conditions of this Seventh Amendment, and the Agreement, this Seventh Amendment shall prevail. 

	II.	AMENDMENTS TO AGREEMENT 

 2.0 License Grant 

Section 2.2(a) of the Agreement is hereby deleted and replaced in its entirety with the following: 

2.2 Trademark License Grant 
 (a)
Genentech hereby grants to Vidara an exclusive license to use the trademark, ACTIMMUNE, for the advertising, promotion, marketing, distribution and sale of License Products in the Territory. Vidara shall have the right to grant sublicenses of such
exclusive license, subject, however, to the prior written consent of Genentech, which consent shall not be unreasonably withheld or delayed. 
 5.0
Intellectual Property Rights 
 A new Section 5.7 is hereby added to the Agreement to read in its entirety as follows: 

5,7 Trademark Maintenance. Genentech shall protect and maintain the ACTIMMUNE trademark in the Territory, including, without limitation,
renewing and maintaining in full force U.S. Trademark Registration No, 1,617,288 for the word mark ACTIMMUNE (hereinafter “U.S. Trademark Registration”), as well as Canadian Registration No. (373897) and Japanese Registration No. [to
be filed upon written request by Vidara] (collectively “Trademark Registrations”). 
 Genentech shall be responsible for renewing
and maintaining the U.S. Trademark Registration, and any other trademark registration for the ACTIMMUNE mark in the Territory, in good standing, including the timely payment of all renewal fees, maintenance fees, government fees or the like,
necessary to so maintain the Trademark Registrations and any foreign counterparts. Genentech shall defend against any cancellation, challenge or like proceeding brought in the U.S. Patent and Trademark Office, or any like office in the Territory,
against the ACTIMMUNE mark and shall bear all such fees and costs, including attorney fees, associated therewith. 
 Genentech shall not
assign the ACTIMMUNE mark or Trademark Registrations to any third party without the prior written consent of Vidara, and any such assignment shall be subject to this Agreement. 

8.0 Up-Front Payment, Milestone Payments and Royalties 

A new Section 8.3(f) is hereby added to the Agreement to read in its entirety as follows: 

8.3(f) Notwithstanding anything herein to the contrary, effective May 5, 2018, and extending for the remainder of the Term of the
Agreement, Vidara shall pay Genentech the following royalties on Net Sales of Licensed Products by Vidara and its sublicensees as sole compensation to Genentech for all trademark rights granted under this Agreement: 

  

					
	 Execution Version
	  	2	  	

 (i) For annual aggregate Net Sales of all Licensed Products in the Territory of up to and
including ***                     , a royalty rate of *** of such Net Sales; 

(ii) For annual aggregate Net Sales of all Licensed Products in the Territory exceeding
***                     , a royalty rate equal to *** of such Net Sales exceeding ***. 

11.0 Term and Termination 

Section 11.1 of the Agreement is hereby deleted and replaced in its entirety with the following: 

11.1 Term. This Agreement shall commence on the Effective Date of this Agreement and, unless terminated earlier, shall expire: 

(a) With respect to Licensed Protein Products, at the later to occur of (i) the expiration of the last to expire of any Genentech Patent
Rights covering a Licensed Protein Product; (ii) twenty (20) years from the Effective Date of this Agreement; or (iii) upon Vidara or Vidara’s successors, licensees or assignees, permanently ceasing, without intending to resume,
the sale of Licensed Product in every country that comprises the Territory; and 
 (b) With respect to Licensed Gene Products, at the
expiration of the last to expire of any Genentech Patent Rights covering a Licensed Gene Product; 
 provided however, that in the
event that either the CMCC License or the Biogen License is terminated, the licenses granted by Genentech to Connetics under the CMCC License or the Biogen License shall also terminate. Genentech shall use its Best Efforts to keep the CMCC License
and the Biogen License in effect during the term of this Agreement, provided, however, that if Connetics declines to pay a CMCC benchmark payment as outlined in Section 5.2(c) or pay any royalty owed to CMCC under the CMCC License for the sales
of Licensed Products, then Genentech shall not be obligated to make such payment and Genentech shall have the option, in its sole discretion, to terminate the CMCC Licensee. 

Section 11.6 of the Agreement is hereby deleted in its entirety and replaced in its entirety with the following: 

11.6 Unilateral Termination. Genentech shall not have the right to unilaterally terminate this Agreement, provided that Genentech may
terminate this Agreement in accordance with Section 11.2 (Termination for Default). In addition to any other right of termination provided herein, Vidara shall have the right to terminate this Agreement for any reason, with or without cause,
upon six (6) months prior written notice to Genentech. If Vidara terminates this Agreement pursuant to this Section 11.6, Vidara agrees that for the following three (3) years it will not use, sell or acquire from any third party
(whether by license or otherwise) any Licensed Product in the Field of Use. If Vidara terminates this Agreement pursuant to this Section 11.6, 

  
  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

  

					
	 Execution Version
	  	3	  	

 
the licenses granted hereunder shall terminate and Genentech shall automatically have all of the rights set forth in Sections 11.3(a) and (b) of this Agreement. 

 

	III.	MISCELLANEOUS 

  

	 	1.	Counterparts. This Seventh Amendment may be executed in counterparts (including signatures by facsimile), each of which shall be deemed an original, but all of which together shall constitute but one and the same
Seventh Amendment. 

  

	 	2.	Warranty of Authority. Each signatory below warrants that he/she is the authorized agent of the respective Party he/she represents and that he/she has the authority to enter into the Seventh Amendment and to bind
the Party thereto 

  

	 	3.	Severability. If any provision of this Seventh Amendment is held to be invalid by any court of competent jurisdiction, then the remaining provisions shall nevertheless remain in full force and effect. The parties
agree to re-negotiate any term held invalid and to be bound by the mutually agreed upon substitute provision. 

 IN WITNESS WHEREOF; the
parties hereto have caused this Seventh Amendment to the Agreement to be executed by two of their duly authorized representatives: 
  

									
	GENENTECH, INC.	 		 	VIDARA THERAPEUTICS INTERNATIONAL LTD.
					
	By: 	 	/s/ Steve Krognes	 		 	By: 	 	/s/ Samira Saya
	Name: Steve Krognes	 		 	Name: Samira Saya
	Title: Chief Financial Officer	 		 	Title: Director
	Dated: 12/18/13	 		 	Dated: 17th December 2013

  

					
	 Execution Version
	  	4EX-10.12

 Exhibit 10.12 

Confidential 
 ASSIGNMENT
AND OPTION AGREEMENT 
 BY AND BETWEEN 

INTERMUNE PHARMACEUTICALS, INC. 

AND 
 CONNETICS
CORPORATION 
 JUNE 23, 2000 

(SUPERSEDING AND REPLACING THE AMENDED AND RESTATED EXCLUSIVE 

SUBLICENSE AGREEMENT OF APRIL 27, 1999) 

 ASSIGNMENT AND OPTION AGREEMENT

 THIS ASSIGNMENT AND OPTION AGREEMENT
(the “Agreement”) is made effective and entered into as of June 23, 2000 (the “Effective Date”) by and between CONNETICS CORPORATION, a Delaware corporation, with a principal place of
business at 3400 West Bayshore Road, Palo Alto, CA 94303 (“Connetics”), and INTERMUNE PHARMACEUTICALS, INC., a Delaware corporation, with a principal place of business at
1710 Gilbreth Road, Suite 301, Burlingame, CA 94010 (“InterMune”). Connetics and InterMune may be referred to herein as a “Party” or collectively as the “Parties.” 

RECITALS 
 A.
WHEREAS, InterMune is a corporation formed for the purpose of research and development of biopharmaceutical products for the treatment of infectious and autoimmune diseases; and 

B. WHEREAS, Connetics has licensed the rights to certain immunology-based products and to the technology relating thereto
from Genentech, Inc. (“Genentech”) pursuant to that certain License Agreement for Interferon Gamma by and between Connetics and Genentech, dated May 5, 1998, as amended (the “Genentech License”); and 

C. WHEREAS, InterMune and Connetics have entered into that certain Amended and Restated Exclusive Sublicense Agreement,
dated April 27, 1999 (the “Original Agreement”), pursuant to which (a) Connetics granted an exclusive sublicense to InterMune under the Genentech License to develop, make, have made, import, offer for sale and sell therapeutic
products containing or derived from such immunology-based products and technology for use for certain specific indications, and (b) InterMune granted to Connetics the exclusive option to practice such sublicensed rights in the dermatology
field; and 
 D. WHEREAS, InterMune and Connetics now desire to supersede and replace the Original Agreement as further
set forth herein in order to assign to InterMune Connetics’ entire right, title and interest in, to and under the Genentech License. 

NOW, THEREFORE, the Parties agree as follows: 

 

	1.	DEFINITIONS 

 1.1 “Affiliate” means
any company or entity controlled by, controlling or under common control with a Party. As used in this Section, “control” means (a) that an entity or company owns, directly or indirectly, fifty percent (50%) or more of the voting
stock of another entity, or (b) that an entity, person or group has the actual ability to control and direct the management of the entity, whether by contract or otherwise, but excluding, for all purposes of this Agreement, Connetics, as to
InterMune, and InterMune, as to Connetics. 
 1.2 “Amendment No. 3” means that certain Amendment No. Three to
License Agreement entered into between Connetics and Genentech, effective April 27, 1999. For clarity, the phrase “as amended by Amendment No. 3” as used herein is intended only for ease of reference and not as a limitation.

  
 1 

 1.3 “Best Efforts” means every necessary and prudent effort of a Party applied
in a prompt, commercially reasonable manner, to the maximum extent reasonably allowed by such Party’s available financial resources, taking into account all of such Party’s business commitments for such financial resources. 

1.4 “BLA” means a Biologics License Application. 

1.5 “Connetics Know-How” means all Know-How in the areas of quality assurance/ quality control (QA/QC), pharmaceutical
science, process development or regulatory affairs that (a) is Controlled by Connetics during the term of this Agreement, and (b) is necessary or useful to the discovery, development, use or manufacture of Products, but excluding all
Know-How that is part of the Genentech License Rights. 
 1.6 “Controlled” means with respect to any material,
Know-How or intellectual property right, that the Party owns or has a license to such material, Know-How or intellectual property right and has the ability to grant access, a license, or a sublicense to such material, Know-How or intellectual
property right to the other Party as provided for herein without violating an agreement with a Third Party as of the time the Party would be first required hereunder to grant the other Party such access, license or sublicense. 

1.7 “Dermatology Field” means the administration to humans of therapeutic products for the treatment, prevention or diagnosis
of any dermatological disease or condition, including, without limitation, atopic dermatitis, keloids/hypertrophic scars, pustular psoriasis and scleroderma, but excluding (a) any cancer disease or condition, (b) any infectious disease or
condition, and (c) any indication outside of the IG Field. 
 1.8 “Dermatology Sublicensee” means a Third Party
to which Connetics has granted a sublicense under the sublicense rights to be granted by InterMune to Connetics following Connetics’ exercise of its option pursuant to Section 4.1. 

1.9 “FDA” means the U.S. Food and Drug Administration, or any successor agency. 

1.10 “Gene Therapy” means the therapeutic or prophylactic treatment of a human being with: (a) one or more
oligonucleotides or nucleotide sequences, in native form or chemically modified, which are introduced into the body in free form, bound to a carrier molecule, contained in any molecular vesicle (e.g. a liposome), incorporated into or attached to a
vector of any type, contained in any cellular construct and/or contained in any mechanical device or (b) cells which have been manipulated ex vivo using one or more oligonucleotides or nucleotide sequences. 

1.11 “Gene Therapy Field” means the administration to humans of Licensed Gene Product for Gene Therapy for the treatment or
prevention of any human disease or condition, provided however, that “Gene Therapy Field” shall not include any treatment or prevention of any type of cardiac or cardiovascular disease or condition. 

1.12 “Genentech” means Genentech, Inc., a Delaware corporation, with its principal office at 1 DNA Way, South San Francisco,
CA 94080. 

  
 2 

 1.13 “Genentech License” means the License Agreement for Interferon Gamma
between Genentech and Connetics, dated May 4, 1998; as amended by: Amendment No. 1 to License Agreement, effective December 28, 1998; Amendment No. 2 to License Agreement, effective January 15, 1999; Amendment No. 3;
and that certain Consent to Assignment Agreement, dated as of the date hereof. 
 1.14 “Genentech License Rights”
means all rights under Patents, Know-How and trademarks granted to Connetics by Genentech under the Genentech License, but only to the extent the Genentech License permits the practice of such rights for the uses set forth in Article 3 herein.
“Genentech License Rights” shall not include any Third Party Product Rights. 
 1.15 “Genentech Patents”
means all the Patent rights which are granted to Connetics under the Genentech License. 
 1.16 “Genentech Supply Agreement”
means the Supply Agreement entered into between Genentech and Connetics dated May 4, 1998. 
 1.17 “IG Field”
means the administration to humans of Licensed Protein Product for the treatment or prevention of any human disease or condition, provided however, that “IG Field” shall not include: (a) the administration to humans of Licensed
Protein Product for the treatment or prevention of any type of arthritis or cardiac or cardiovascular disease or condition or (b) use of Licensed Protein Product for Gene Therapy. 

1.18 “Interferon Gamma” or “IG” means the polypeptide described as “Interferon Gamma” in Section 1.20
of the Genentech License. 
 1.19 “InterMune Net Sales” means “Net Sales” of Licensed Protein Products in
the Territory for use in the IG Field by InterMune and its sublicensees hereunder other than Connetics and its Affiliates and Dermatology Sublicensees. 

1.20 “Know-How” means all information, data, know-how, trade secrets, inventions, developments, results, techniques and
materials, whether or not patentable. 
 1.21 “Licensed Product,” “Licensed Gene Product” and “Licensed
Protein Product” shall each have the same meaning as defined in Section 1.22 of the Genentech License. 
 1.22
“Licensed Technology” means the Genentech License Rights and the Connetics Know-How. 
 1.23 “Net Sales” means
“Net Sales” (as defined in Section 1.25 of the Genentech License) of Licensed Protein Products in the Territory for use in the IG Field by InterMune and any of its sublicensees hereunder (including without limitation Connetics, its
Affiliates and its Dermatology Sublicensees). 
 1.24 “Original Agreement Effective Date” means April 27, 1999.

  
 3 

 1.25 “Patents” means any and all issued or pending patents and patent
applications, both foreign and domestic, and including without limitation (a) all divisionals, continuations and continuations-in-part of any such applications, (b) any patents that issue from any of the foregoing, and (c) all
substitutions, extensions, reissues, renewals, supplementary protection certificates and inventors’ certificates with respect to any of the foregoing issued patents. 

1.26 “Territory” shall have the meaning set forth in Section 1.28 of the Genentech License. 

1.27 “Third Party” means any party besides the Parties and their respective Affiliates. 

1.28 “Third Party Product Rights” shall have the meaning set forth in Section 1.37 of the Genentech License. 

1.29 United States” means the United States and its territories and possessions. 

 

	2.	ORIGINAL AGREEMENT SUPERSEDED 

The Parties agree that the Original Agreement is hereby replaced and superseded in all respects by this Agreement as of the Effective Date,
except as expressly set forth in Section 3.3. 
  

	3.	ASSIGNMENT OF RIGHTS; LICENSE GRANT; RELATED COVENANTS 

3.1 Assignment of Rights. Connetics agrees to assign and hereby does assign to InterMune Connetics’ entire right, title and
interest in, to and under the Genentech License. Upon each request by InterMune, without additional consideration, Connetics agrees to promptly execute all documents and take all such acts as InterMune deems necessary or desirable to procure,
maintain, perfect, and enforce the full benefits, enjoyment, rights, title and interest in, to and under the Genentech License assigned hereunder. In the event InterMune is unable for any reason, after reasonable effort, to secure Connetics’
signature on any document needed in connection with the actions specified herein, Connetics hereby irrevocably designates and appoints InterMune and its duly authorized officers and agents as its agent and attorney in fact, which appointment is
coupled with an interest, to act for and on its behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of this Section 3.1 with the same legal force and effect as if executed by
Connetics. Connetics agrees that as of the Effective Date, InterMune shall be deemed a party to and sole licensee under the Genentech License, and that Connetics shall have no further rights nor obligations thereunder, except as set forth in
Section 4.1 of this Agreement and those obligations that accrued prior to the Effective Date, including without limitation, Connetics’ remaining obligations, if any, under Section 8.1 of the Genentech License. Connetics hereby
covenants that it shall take no action inconsistent with InterMune’ s rights as party to and licensee under the Genentech License. 

3.2 Connetics Know-How. Connetics hereby grants to InterMune a non-exclusive license under the Connetics Know-How to develop, use, make,
have made, import, offer for sale and sell (a) Licensed Products in the Territory, and (b) any products covered by Third Party Product Rights to which Connetics or InterMune acquires rights under the Genentech License in the applicable
territory. 

  
 4 

 3.3 Genentech Supply Agreement. Pursuant to the Original Agreement, Connetics assigned to
InterMune Connetics’ entire right, title and interest to the Genentech Supply Agreement, which assignment shall remain in full force and effect. InterMune hereby covenants that it shall maintain the Genentech Supply Agreement effective and in
good standing. To the extent Connetics exercises its option pursuant to Section 4.1 below, InterMune shall procure for and supply to Connetics (and its Dermatology Sublicensees, if any) its requirements for Bulk Product and Finished Product (as
such terms are defined in the Genentech Supply Agreement) for use in the Dermatology Field from Genentech pursuant to the Genentech Supply Agreement or from any Third Party manufacturer(s) contracted by InterMune to manufacture Finished Product and
Bulk Product, provided that Connetics shall pay to InterMune InterMune’s cost, without markup, for procuring and supplying such Finished Product and Bulk Product to Connetics. 

3.4 Transfer of Data and Materials. Promptly following the Effective Date, Connetics and InterMune shall work cooperatively together to
transfer to InterMune all documents or materials in Connetics’ possession comprising or containing the Licensed Technology, including without limitation, biological and chemical materials, regulatory filings, and data, and Connetics shall
transfer any and all additions or improvements to the Licensed Technology to InterMune as soon as is reasonably practicable after the creation, development or acquisition of such addition or improvements. 

 

	4.	OPTION TO DERMATOLOGY RIGHTS 

4.1 Option Grant. InterMune hereby grants to Connetics the exclusive option to obtain the exclusive sublicense under the Genentech
License Rights to develop, use, make, have made, import, offer for sale and sell Licensed Protein Products for use solely in the Dermatology Field in the United States, subject to Genentech’s rights under the Genentech License. Connetics may
exercise such option at any time prior to the fifth anniversary of the Original Agreement Effective Date by providing InterMune written notice of its desire to exercise such option. Upon InterMune’s receipt of such notice, InterMune shall be
deemed to have granted to Connetics the exclusive, royalty-free (with respect to InterMune only), sublicense under the Genentech License Rights to use, make, have made, import, offer for sale and sell Licensed Protein Products in the Dermatology
Field in the United States for the term of this Agreement, subject to the terms of the Genentech License and of this Agreement, and Connetics shall be subject to all terms and conditions of the Genentech License relating to its development and
commercialization of Licensed Protein Products in the Dermatology Field in the United States, including without limitation those obligations described in Sections 4.2 and 4.5 below. Such sublicense shall be further sublicenseable by Connetics to the
extent permitted by the Genentech License. If not exercised by the fifth anniversary of the Original Agreement Effective Date, the option granted in this Section 4.1 shall expire. 

4.2 Milestone Payments. If Connetics exercises its option under Section 4.1 then: 

(a) In the event that Connetics or a Dermatology Sublicensee achieves one of the milestones set forth in Sections 8.2(a) or (b) of
the Genentech License with respect to a Licensed Protein Product, Connetics or such Dermatology Sublicensee shall inform InterMune thereof and provide such milestone payment due under the Genentech License to InterMune. 

  
 5 

 (b) In the event that milestone payments to Genentech as set forth in Sections 8.2(c) and
(d) of the Genentech License are triggered by the sale of Licensed Protein Products by both Connetics and InterMune (and/or their sublicensees) in the Territory, the Parties shall promptly meet and in good faith determine a fair apportionment
between the Parties of the payment to be made to Genentech for such milestone based upon the relative Net Sales of each Party for such calendar year or other agreed upon method of apportionment. Connetics shall then submit to InterMune its portion
of such milestone payment in accordance with the terms of the Genentech License. 
 4.3 Royalties. If Connetics exercises its option
under Section 4.1 then: 
 (a) Connetics shall pay royalties to InterMune on all Net Sales of Licensed Protein Products by
Connetics, its Affiliates and its Dermatology Sublicensees at the applicable royalty rate set forth in Section 8.3 of the Genentech License (as may be reduced pursuant to Section 8.4 of the Genentech License). 

(b) Royalty payments shall be made to InterMune quarterly within sixty (60) days following the end of each calendar quarter for
which royalties are due. Each royalty payment shall be accompanied by a report summarizing the total Net Sales by Connetics, its Affiliates and its Dermatology Sublicensees during-the relevant
three-month period, and the calculation of royalties, if any, due thereon pursuant to subsection (a) above. 
 (c) Connetics, its
Affiliates and its Dermatology Sublicensees hereunder shall keep full, true and accurate books of account containing all particulars which may be necessary for the purpose of showing Net Sales. Said books of account shall be kept at the principal
place of business of Connetics, its Affiliates or its Dermatology Sublicensees, as the case may be. Said books and the supporting data shall be open at all reasonable times, for three (3) years following the end of the calendar year to which
they pertain (and access shall not be denied thereafter, if reasonably available), to the inspection of an independent public accountant retained by InterMune or Genentech and reasonably acceptable to Connetics (or its Affiliate or Dermatology
Sublicensee) for the purpose of verifying Net Sales under this Agreement; subject to the provisions of subsection (e) below. 
 (d)
Connetics shall, within sixty (60) days after the end of each calendar quarter beginning with the quarter of the first commercial sale of a Licensed Protein Product in the Dermatology Field in the Territory by Connetics, its Affiliates or
its Dermatology Sublicensees, deliver to InterMune a true and accurate report, setting forth such particulars of the business conducted by Connetics, its Affiliates and its Dermatology Sublicensees during the preceding quarter as are pertinent to an
accounting for Net Sales and deductible expenses as permitted under the Genentech License. Such reports shall include at least the following: (i) the total gross sales of Licensed Protein Products occurring during that calendar quarter,
(ii) the allowable deductions therefrom, (iii) the total Net Sales of Licensed Protein Products occurring during that calendar quarter and (iv) the calculation of royalties, if any, due thereon pursuant to subsection (a) above.

 (e) At InterMune’s or Genentech’s request and expense, Connetics shall permit a certified public accountant selected by
InterMune or Genentech and reasonably 

  
 6 

 
acceptable to Connetics to examine, not more than once in any four consecutive calendar quarters during the term of this Agreement, but including one (1) post-termination audit,
Connetics’ books of account and records of all sales of Licensed Protein Products by Connetics, its Affiliates and its Dermatology Sublicensees for the sole purpose of determining the correctness of the reports provided by Connetics under
subsection (a) above. If such accountant reasonably determines that the royalties owed by Connetics to InterMune under subsection (a) above have been, for any calendar year in total, understated by Connetics, Connetics shall immediately
pay to InterMune all understated royalties, together with interest on such royalties from the date accrued at a rate of prime plus 2% and shall pay the reasonable costs of the examination if Connetics has understated such royalties by more than 5%.

 4.4 Off-Label Sales. If Connetics exercises the option set forth in Section 4.1 then: 

(a) Each Party agrees and shall require its sublicensees, if any, to use commercially reasonable efforts to formulate all Licensed
Protein Products developed by such Party or sublicensee thereof in a manner to reduce, to the extent reasonably practicable, the possibility that such Licensed Protein Product can be used in the other Party’s field of use as provided hereunder.
If a Party cannot so formulate a particular Licensed Protein Product, then such Party agrees to use its Best Efforts to prevent sales of such Licensed Protein Product for use in the other Party’s field of use, including without limitation
instructing its sales forces, and requiring all sublicensees to instruct their sales forces, that such Licensed Protein Product is not to be promoted, marketed or sold for use in the other Party’s field of use. 

(b) In the event that either Party determines that a Licensed Protein Product sold by a Party or its sublicensees hereunder is being
used in a field of use other than one for which such Party has the right to sell such Licensed Protein Product hereunder, the Party making such determination shall immediately inform the other Party. The Parties shall then promptly meet and
diligently and in good faith determine a fair and reasonable mechanism for equitable allocation of the sales of such Licensed Protein Product that are used outside the field of use for which the selling Party had the right to sell. 

4.5 Patent Costs. If Connetics exercises the option set forth in Section 4.1, then Connetics agrees to reimburse InterMune all
costs paid by InterMune to Genentech under Section 5.2 of the Genentech License which relate to any patent or patent application the claims of which: (a) are specifically directed to a Licensed Protein Product for use in the Dermatology
Field and (b) do not relate to a Licensed Protein Product for use in any area of the IG Field other than the Dermatology Field. 

4.6 Milestone Payments. If Connetics exercises its option under Section 4.1, then Connetics shall make the following cash milestone
payments to InterMune: 
 (a) One million two hundred thousand dollars ($1,200,000) within thirty (30) days following the date on
which the first NDA or BLA for a Licensed Protein Product is filed with the FDA by Connetics, its Affiliate or its Dermatology Sublicensee for an indication in the Dermatology Field; and 

  
 7 

 (b) Two million dollars ($2,000,000) within thirty (30) days following the date
Connetics, its Affiliate or its Dermatology Sublicensee receives FDA clearance for each new indication in the Dermatology Field of a Licensed Protein Product for commercial sale in the United States. 

4.7 Dermatological Indications Outside of the Dermatology Field. 

(a) It is the intention of the Parties that Connetics shall be InterMune’s preferred marketing partner for sales of Licensed
Protein Product to dermatologists in the United States during the term of this Agreement. Therefore, during the term of this Agreement, if either Party desires to sell Licensed Protein Product to dermatologists in the United States for use for
indications that are outside of the Dermatology Field but within the IG Field (an “Outside Indication”), the provisions of this Section 4.7 shall apply. 

(b) In the event that either Party desires to sell a Licensed Protein Product for an Outside Indication to dermatologists in the United
States during the term of this Agreement, such Party shall give the other Party written notice of such interest, which notice shall specify the indication of interest. If InterMune notifies Connetics that InterMune itself desires to sell such
Licensed Protein Product for an Outside Indication directly to dermatologists in the United States, then the procedures of subsection (d) shall apply. Otherwise, for ninety (90) days following receipt of such notice, the Parties shall
exclusively negotiate in good faith for the reasonable commercial terms under which Connetics shall exclusively sell such Licensed Protein Product for such Outside Indication to dermatologists in the United States. In the event that, at the end of
such ninety (90) day period, the Parties have failed to enter into a written agreement on such commercially reasonable terms, Connetics’ rights with respect to the sale of such Licensed Protein Product for such Outside Indication shall
terminate and InterMune shall have no further obligations to Connetics under this Section 4.7 with respect to such Licensed Protein Product for such Outside Indication except as set forth is subsections (c) and (d) below. 

(c) If the Parties have failed to enter into an agreement by the end of such ninety (90) day period, as described in subsection
(b) above, InterMune shall then have the right during the following one hundred eighty (180) day period to enter into an agreement with a Third Party for the sale to dermatologists of such Licensed Protein Product for such Outside
Indication on economic terms that, taken as a whole, are substantially the same as, or more favorable to InterMune than, those last offered in writing by Connetics for such rights pursuant to subsection (b) above. If at the end of such one
hundred eighty (180) day period InterMune has not entered into an agreement with a Third Party to sell such Licensed Protein Product for such Outside Indication to dermatologists in the United States, then the procedures set forth in subsection
(b) above shall again apply, provided that InterMune may proceed alternatively under subsection (d) below. 
 (d) If InterMune
itself desires to sell such Licensed Protein Product to dermatologists in the United States for Outside Indications, then upon written notice from InterMune, Connetics and InterMune shall enter into good faith negotiations, for a period of ninety
(90) days from Connetics’ receipt of such notice, for the reasonable commercial terms upon which InterMune shall grant to Connetics the rights to co-promote such Licensed Protein Product for such Outside Indication to dermatologists in the
United States. InterMune agrees 

  
 8 

 
that it shall not unreasonably withhold its agreement to such commercially reasonable terms. In the event that, at the end of such ninety (90) day period, the Parties have failed to enter
into a written agreement for such co-promotion rights, InterMune shall have no further obligations to Connetics under this Section 4.7 with respect to such Licensed Protein Product for such Outside Indication, provided that InterMune may
not enter into an agreement with a Third Party for the rights to co-promote Licensed Protein Product for such Outside Indication to dermatologists in the United States on economic terms that, taken as a whole, are less favorable to InterMune than
those last offered in writing by Connetics for such rights. In the event that InterMune does not enter into such a co-promotion agreement with a Third Party and instead solely promotes and sells such Licensed Protein Product for such Outside
Indication to dermatologists in the United States itself, if at any time following such sole promotion and sale InterMune determines in its sole discretion that it desires to grant a license to the rights to promote and sell, or to co-promote, such
Licensed Protein Product for such Outside Indication to dermatologists in the United States to a Third Party, then the procedures set forth in subsection (b) above shall apply. 

 

	5.	CONSIDERATION 

 5.1 Royalties. 

(a) Beginning on January 1, 2002, InterMune shall pay to Connetics a royalty of one-quarter of one percent (0.25%) of InterMune Net
Sales in the United States. InterMune shall continue to pay such royalties to Connetics until such time as the cumulative InterMune Net Sales in United States, beginning on January 1, 2000, are equal to one billion dollars ($1,000,000,000).
Thereafter, InterMune shall pay to Connetics a royalty of one-half of one percent (0.5%) of InterMune Net Sales in the United States for the remainder of the term of the Agreement. 

(b) All royalties due under this Section 5.1 shall be due and payable quarterly within thirty (30) days following the last day
of each quarter in which royalties are incurred beginning with first calendar quarter of 2002. 
 5.2 Milestone Payment. InterMune
shall pay to Connetics a milestone payment of one million five hundred thousand dollars ($1,500,000), (the “Milestone Payment”), payable in a lump sum or in installments based on the level of InterMune Net Sales, as follows: 

(a) If annualized InterMune Net Sales in the United States for 2001, based on InterMune Net Sales in the United States for the third and
fourth calendar quarters of 2001, (“2001 Net Sales”) are equal to or greater than twenty million dollars ($20,000,000), then on March 31, 2002, InterMune shall, at its election, either (i) pay the full Milestone Payment to
Connetics, or (ii) pay to Connetics three hundred seventy five thousand dollars ($375,000) of the Milestone Payment and furnish to Connetics a promissory note for the balance of the Milestone Payment, which promissory note shall provide for
three (3) principal payments to Connetics of three hundred seventy five thousand dollars ($375,000) each due upon June 30, 2002, September 30, 2002 and December 31, 2002, respectively. 

(b) If 2001 Net Sales are equal to or greater than fifteen million dollars ($15,000,000) but less than twenty million dollars
($20,000,000), then on March 31, 2002, 

  
 9 

 
InterMune shall pay to Connetics three hundred thousand dollars ($300,000) of the Milestone Payment, and furnish to Connetics a promissory note for the balance of the Milestone Payment (the
“Remaining Payment”), which promissory note shall provide for full payment of the balance of such note to Connetics on the earlier to occur of (i) March 31, 2004, or (ii) the last day of the month following the consecutive
twelve (12) month period that InterMune Net Sales in the United States are equal to or greater than twenty million dollars ($20,000,000), subject to subsection (d) below. 

(c) If 2001 Net Sales are less than fifteen million dollars ($15,000,000), then on March 31, 2002, InterMune shall pay to Connetics
a portion of the Milestone Payment equal to three hundred thousand dollars ($300,000) multiplied by a fraction, the numerator of which is 2001 Net Sales and the denominator of which is twenty million dollars ($20,000,000). InterMune shall furnish to
Connetics a promissory note for the balance of the Milestone Payment (the “Remaining Payment”), which promissory note shall provide for full payment of the balance of such note to Connetics on the earlier to occur of
(i) March 31, 2004, or (ii) the last day of the month following the consecutive twelve (12) month period that InterMune Net Sales in the United States are equal to or greater than twenty million dollars ($20,000,000), subject to
subsection (d) below. 
 (d) With respect to the promissory note for the Remaining Payment described in subsection (b) or
(c) above, if InterMune is to pay the balance of such note on March 31, 2004, and InterMune Net Sales in the United States for the twelve (12) month period preceding March 31, 2004 are equal to or greater than ten million dollars
($10,000,000) but less than twenty million dollars ($20,000,000), then: 
 (i) InterMune may, at its election, pay fifty percent
(50%) of the Remaining Payment either in cash or in Preferred Shares of InterMune stock at the fair market value of such shares, determined as the average closing price of such shares over the previous thirty (30) day period; and 

(ii) With respect to the other fifty percent (50%) of the Remaining Payment, Connetics may, at its election, receive such fifty
percent either in cash or in Preferred Shares of InterMune stock at the fair market value of such shares, determined as the average closing price of such shares over the previous thirty (30) day period, provided that Connetics shall notify
InterMune of its election in writing at least thirty (30) days prior to the date that such payment is due. 
 (e) With respect to
the Remaining Payment described in subsection (b) or (c) above, if InterMune is to pay the balance of such note on March 31, 2004, and InterMune Net Sales in the United States for the twelve (12) month period preceding
March 31, 2004 are less than ten million dollars ($10,000,000), then InterMune may, at its election, either: 
 (1) Pay such
Remaining Payment in cash or in Preferred Shares of InterMune stock at the fair market value of such shares, determined as the average closing price of such shares over the previous thirty (30) day period; or 

  
 10 

 (2) Grant to Connetics the license to the Accounting and Revenue Rights to CGD Units (as
defined below), on commercially reasonable terms to be agreed upon by the Parties, in which event InterMune shall thereafter have no further obligation to Connetics with respect to such Remaining Payment. Such license shall be fully paid-up solely
with respect to InterMune but not with respect to Genentech or any other Third Party, and shall expire upon the date of expiration of the last to expire Genentech Patent covering the manufacture, use or sale of Licensed Products for the treatment of
CGD in the United States and its territories and possessions. As used herein, “Accounting and Revenue Rights to CGD Units” means the right to book net revenues, expenses and net profits for the sales of Licensed Products for the treatment
of chronic granulomatous disease by InterMune and its sublicensees in the United States. 
 (f) All promissory notes referred
to in this Section 5.2 shall bear interest at the rate of the prime rate plus two percentage points (2%). 
 5.3 Reports; Audit
Rights. InterMune shall provide to Connetics a copy of all reports submitted to Genentech by InterMune pursuant to Section 8.8 of the Genentech License when InterMune submits such report to Genentech. Following January 1, 2002,
Connetics shall have the same audit rights as Genentech pursuant to Section 8.8 of the Genentech License. 
 5.4 Third Party
Royalties. Each Party shall be responsible for paying all royalties due to Third Parties other than Genentech under Section 8.4 of the Genentech License with respect to such Party’s and its sublicensees’ activities hereunder.

 6. INTELLECTUAL PROPERTY 

6.1 Ownership of Inventions. Each Party shall remain the sole owner of its respective technology and other intellectual property that it
owned as of the Effective Date. A Party shall not have or acquire any rights in any inventions, Know-How or intellectual property rights of the other Party, except as specifically granted herein. 

6.2 Infringement of Third Party Patents. In the event that a Third Party files an action against a Party alleging that such Party’s
activities under this Agreement infringe such Third Party’s patent rights, such Party shall give written notice to the other Party, and the Parties will consult and cooperate on the best course of action. The Party that was sued shall have the
right to defend itself against such action, and the other Party shall provide all reasonable assistance in such defense. 
 6.3
Infringement of Licensed Patents. In the event that either Party becomes aware that a Third Party is infringing any rights in the Genentech Patents, such Party shall promptly notify the other. InterMune shall have the right to enforce the
Genentech Patents to the full extent permitted under the Genentech License, and Connetics will reasonably cooperate with InterMune in such enforcement actions and take all reasonably necessary steps to facilitate InterMune’s enforcement of the
Genentech Patents. 
 6.4 Cooperation. Each Party agrees to cooperate with the other and take all reasonable additional actions
as may be reasonably required to achieve the intent of this Article 

  
 11 

 
6, including, without limitation, the execution of all necessary and appropriate instruments and documents. 
  

	7.	REPRESENTATIONS AND WARRANTIES 

7.1 Mutual Representations and Warranties. Each Party hereby represents and warrants to the other Party as follows: 

(a) Such Party (i) is duly organized, validly existing and in good standing under the laws of the state in which it is organized;
(ii) has the power and authority and the legal right to own and operate its property and assets, to lease the property and assets it operates under lease, and to carry on its business as it is now being conducted; and (iii) is in
compliance with all requirements of applicable law, except to the extent that any noncompliance would not materially adversely affect such Party’s ability to perform its obligations under the Agreement. 

(b) Such Party (i) has the power and authority and the legal right to enter into the Agreement and to perform its obligations
hereunder, and (ii) has taken all necessary action on its part to authorize the execution and delivery of the Agreement and the performance of its obligations hereunder. The Agreement has been duly executed and delivered on behalf of such
Party, and constitutes a legal, valid, binding obligation, enforceable against such Party in accordance with its terms. 
 (c) All
necessary consents, approvals and authorizations of all governmental authorities and other persons required to be obtained by such Party in connection with the Agreement have been obtained. 

(d) The execution and delivery of the Agreement and the performance of such Party’s obligations hereunder (i) do not conflict
with or violate any requirement of applicable laws or regulations or any material contractual obligation of such Party, and (ii) do not materially conflict with, or constitute a material default or require any consent under any material
contractual obligation of such Party. 
 7.2 Connetics Representations and Warranties. Connetics hereby represents and warrants that:

 (a) To Connetics’ knowledge as of the Effective Date, the Licensed Technology practiced as permitted herein does not infringe
on any intellectual property rights owned by any Third Party. 
 (b) Connetics possesses the necessary interest, title and right to
the Licensed Technology to grant the licenses and to make the assignments to InterMune hereunder. 
  

	8.	INDEMNIFICATION 

 8.1 Indemnification by Connetics.
Connetics agrees to indemnify, hold harmless and defend InterMune and InterMune’s directors, officers, employees and agents, and the directors, officers, employees and agents of any InterMune Affiliate from and against any and all claims,
suits, losses, damages, costs, fees and expenses resulting from or arising out of any 

  
 12 

 
negligent or wrongful act or omission by Connetics, its Affiliates or its Dermatology Sublicensees, or any breach by Connetics of its obligations under this Agreement or under the Genentech
License, except to the extent that such claims, suits, losses, damages, costs, fees or expenses arises or results from any negligent or wrongful act or omission of InterMune or its Affiliates. 

8.2 Indemnification by InterMune. InterMune agrees to indemnify, hold harmless and defend Connetics and its directors, officers,
employees and agents, and the directors, officers, employees and agents of any Connetics Affiliates or its Dermatology Sublicensees from and against any and all claims, suits, losses, damages, costs, fees and expenses resulting from or arising out
of damage or injury caused by a negligent or wrongful act or omission of InterMune, its Affiliates or its Sublicensees, or any breach by InterMune of its obligations under this Agreement or under the Genentech License, except to the extent that such
claims, suits, losses, damages, costs, fees or expenses arises or results from any negligent or wrongful act or omission of Connetics, its Affiliates or its Dermatology Sublicensees. 

8.3 Indemnification Procedure. In all cases where one Party seeks indemnification by the other under this Article 8, the Party seeking
indemnification shall promptly notify the indemnifying Party of receipt of any claim or lawsuit covered by such indemnification obligation and shall cooperate fully with the indemnifying Party in connection with the investigation and defense of such
claim or lawsuit. The indemnifying Party shall have the right to control the defense, with counsel of its choice, provided that the non-indemnifying Party shall have the right to be represented by advisory counsel at its own expense. The
indemnifying Party shall not settle or dispose of the matter in any manner which could negatively and materially affect the rights or liability of the non-indemnifying Party without the non-indemnifying Party’s prior written consent, which
shall not be unreasonably withheld. 
  

	9.	CONFIDENTIALITY 

 9.1 Confidential Information
Obligations. As used herein, “Confidential Information” means all information that a Party discloses to the other Party under this Agreement or had disclosed to the other Party under the Original Agreement, provided that Confidential
Information shall not include such information excluded under Section 9.2. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, each Party agrees that, during the term of this Agreement and
for five (5) years after the expiration or termination of this Agreement, it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement any Confidential
Information furnished to it by the other Party pursuant to this Agreement. 
 9.2 Exceptions. The obligations set forth in
Section 9.1 shall not apply to any Information that the receiving Party can demonstrate by competent evidence: 
 (a) was
already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the other Party; 

(b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party
by the other Party; 

  
 13 

 (c) became generally available to the public or otherwise part of the public domain after
its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; 
 (d) was disclosed to
the receiving Party, other than under an obligation of confidentiality to a Third Party, by a Third Party who had no obligation to the disclosing Party not to disclose such information to others; or 

(e) is independently developed by the receiving Party without using any of the other Party’s Confidential Information. 

9.3 Terms of the Agreement. The Parties agree that the terms of this Agreement will be considered Confidential Information of both
Parties. Notwithstanding the foregoing, a Party shall have the right to disclose the material financial terms of the Agreement to any bona fide potential investor, investment banker, acquiror, merger partner or other potential financial partner,
subject to such Party obtaining the agreement of such party receiving such Confidential Information to keep such information confidential. 

9.4 Permitted Disclosure. Notwithstanding the limitations in this Article 9, each Party may disclose Confidential Information belonging
to the other Party (or otherwise subject to this Article 9), to the extent such disclosure is reasonably necessary in the following instances, but solely for the limited purpose of such necessity: 

(a) filing or prosecuting Patents; 

(b) regulatory and tax filings; 

(c) prosecuting or defending litigation; 

(d) complying with applicable governmental laws or regulations or valid court orders; 

(e) conducting preclinical or clinical trials of Licensed Products; and 

(f) disclosure to Affiliates, licensees, sublicensees, employees, consultants or agents who agree to be bound by similar terms of
confidentiality and non-use at least equivalent in scope to those set forth in this Article 9. 
 Notwithstanding the foregoing, in the
event a Party is required to make a disclosure of the other Party’s Confidential Information pursuant to Section 9.4, it will give reasonable advance notice to the other Party of such disclosure and endeavor in good faith to secure
confidential treatment of such information. In any event, the Parties agree to take all reasonable action to avoid disclosure of Confidential Information hereunder. Further, the Parties agree to consult with one another on the provisions of this
Agreement to be redacted in any filings made by a Party with the United States Securities and Exchange Commission or as otherwise required by law. 

  
 14 

	10.	TERMINATION 

 10.1 Term of Agreement. The term of
this Agreement shall expire, unless earlier terminated as provided by Section 10.2 below, upon expiration or termination of the Genentech License. 

10.2 Termination for Material Breach. If either Party shall default in a material manner with respect to any material provision of this
Agreement and the other Party shall have given the defaulting Party written notice of such default, the defaulting Party shall have thirty (30) days to cure such default. If such default is not cured within such thirty (30) day period, the
non-defaulting Party shall have the right, upon notice to the defaulting Party and without prejudice to any other rights the non-defaulting Party may have, to terminate this Agreement unless the defaulting Party is in the process of attempting in
good faith to remedy such default, in which case, the thirty (30) day cure period shall be extended by an additional thirty (30) days. 

10.3 Effect of Termination. Upon termination or expiration of the Agreement, (a) all licenses granted by Connetics to InterMune
under Article 3 will terminate; (b) any and all claims and payment obligations that accrued prior to the date of such termination or expiration shall survive such termination; and (c) each Party shall return all of the other Party’s
Confidential Information. 
 10.4 Surviving Rights. The obligations and rights of the Parties under Sections 4.3(c), 5.3, 6.1,
and Articles 8, 9, 10 and 11 shall survive any termination or expiration of the Agreement. 
 10.5 Accrued Rights and Surviving
Obligations. The termination or expiration of the Agreement for any reason shall be without prejudice to any rights, which shall have accrued to the benefit of either Party prior to such termination or expiration, including any damages arising
from any breach hereunder. Such termination or expiration shall not relieve either Party from obligations which are expressly indicated to survive termination or expiration of the Agreement. 

10.6 Bankruptcy Rights. In the event that this Agreement is terminated or rejected by a Party or its receiver or trustee under
applicable bankruptcy laws due to such Party’s bankruptcy, then all rights and licenses granted under or pursuant to this Agreement by such Party to the other Party are, and shall otherwise be deemed to be, for purposes of Section 365(n)
of the Bankruptcy Code and any similar law or regulation in any other country, licenses of rights to “intellectual property” as defined under Section 101(52) of the Bankruptcy Code. The Parties agree that all intellectual property
rights licensed hereunder, including without limitation any patents or patent applications in any country of a Party covered by the license grants under this Agreement, are part of the “intellectual property” as defined under
Section 101(52) of the Bankruptcy Code subject to the protections afforded the non-terminating Party under Section 365(n) of the Bankruptcy Code, and any similar law or regulation in any other country. 

  
 15 

	11.	MISCELLANEOUS 

 11.1 Waiver. No waiver by either
Party hereto of any breach or default of any of the covenants or agreements herein set forth shall be deemed a waiver as to any subsequent or similar breach or default. 

11.2 Assignment. This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their permitted successors and
assigns; provided, however, that neither Party shall assign any of its rights and obligations hereunder without the prior written consent of the other Party, except as incident to the merger, consolidation, reorganization or acquisition of stock or
assets affecting substantially all of the assets or actual voting control of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this Section 11.2 shall be null and void and of no legal
effect. 
 11.3 Notices. Any notice or other communication required or permitted to be given to either Party hereto shall be in
writing and shall be deemed to have been properly given and to be effective on the date of delivery if delivered in person or by facsimile or five (5) days after mailing by registered or certified mail, postage paid, to the other Party at the
following address: 
  

			
	In the case of InterMune:	  	 InterMune Pharmaceuticals, Inc.
 1710 Gilbreth
Road,
 Suite 301
 Burlingame, CA 94010

Fax: (650) 259-0774
 Attention: General Counsel

		
	with a copy to:                	  	 Cooley Godward LLP 
 Five Palo
Alto Square
 3000 El Camino Real
 Palo Alto, CA 94306

Fax: (650) 849-7400
 Attention: Barclay James Kamb,
Esq

		
	In the case of Connetics:	  	 Connetics Corporation
 3400 West Bayshore
Road
 Palo Alto, CA 94303
 Fax: (650) 843-2899

Attention: Chief Executive Officer

 Either Party may change its address for communications by a notice to the other Party in accordance with this Section. 

11.4 Headings. The headings of the several sections are inserted for convenience of reference only and are not intended to be a part of
or to affect the meaning or interpretation of this Agreement. 

  
 16 

 11.5 Amendment. No amendment or modification hereof shall be valid or binding upon the
Parties unless made in writing and signed by both Parties. 
 11.6 Governing Law. This Agreement shall be governed exclusively
by the laws of the State of California, U.S.A., as such law applies to contracts entered into between and to be performed by California residents entirely in the State of California. 

11.7 Dispute Resolution. 

(a) In the event of any controversy or claim arising out of, relating to or in connection with any provision of this Agreement, or the
rights or obligations of the Parties hereunder, the Parties shall try to settle their differences amicably between themselves by referring the disputed matter to the President of InterMune and the Chief Executive Officer of Connetics for discussion
and resolution. Either Party may initiate such informal dispute resolution by sending written notice of the dispute to the other Party, and within ten (10) days after such notice such representatives of the Parties shall meet for attempted
resolution by good faith negotiations. If such personnel are unable to resolve such dispute within thirty (30) days of initiating such negotiations, either Party may seek to have such dispute resolved by binding arbitration under this
Section 11.7. The arbitration shall be held in Palo Alto, California according to the Commercial Arbitration Rules of the American Arbitration Association (the “Rules”). The arbitration will be conducted by a panel of three
(3) arbitrators who are knowledgeable in the subject matter that is at issue in the dispute, are not affiliated directly or indirectly with either Party, and are selected by mutual agreement of the Parties. Failing such agreement, the
arbitrators shall be selected appointed as provided in the Rules. During the arbitration, the Parties shall have such discovery rights as the arbitrators may allow, consistent with the discovery permitted by the Federal Code of Civil Procedure. In
conducting the arbitration, the arbitrators shall apply the rules of evidence applicable in California, and shall be able to decree any and all relief of an equitable nature, including but not limited to such relief as a temporary restraining order,
a preliminary injunction, a permanent injunction, or replevin of property, as well as specific performance. The arbitrators shall also be able to award direct and indirect damages, but shall not award any other form of damage (e.g., punitive or
exemplary damages). The reasonable fees and expenses, of the arbitrators, along with the reasonable legal fees and expenses of the prevailing Party (including all expert witness fees and expenses), the fees and expenses of a court reporter, and any
expenses for a hearing room, shall be paid as follows: If the arbitrators rule in favor of one Party on all disputed issues in the arbitration, the losing Party shall pay one hundred percent (100%) of such fees and expenses; if the arbitrators
rule in favor of one Party on some issues and the other Party on other issues, the arbitrators shall issue with the rulings a written determination as to how such fees and expenses shall be allocated between the Parties. The arbitrators shall
allocate fees and expenses in a way that bears a reasonable relationship to the outcome of the arbitration, with the Party prevailing on more issues, or on issues of greater value or gravity, recovering a relatively larger share of its legal fees
and expenses. The decision of the arbitrators shall be final and may be entered, sued on or enforced by the Party in whose favor it runs in any court of competent jurisdiction at the option of such Party. Whether a claim, dispute or other matter in
question would be barred by the applicable statute of limitations, which statute of limitations also shall apply to any claim or disputes subject to arbitration under this Section, shall be determined by binding arbitration pursuant to this Section.

  
 17 

 (b) Notwithstanding anything to the contrary in this Agreement, either Party may seek
immediate injunctive or other interim relief without resort to arbitration from any court of competent jurisdiction with respect to any breach of Article 9 hereof, or as necessary to enforce and prevent infringement of the patent rights, copyright
rights, trademarks, trade secrets, or other intellectual property rights owned or controlled by a Party or its Affiliates. 
 11.8 Force
Majeure. Any delays in performance by any Party under this Agreement shall not be considered a breach of this Agreement if and to the extent caused by occurrences beyond the reasonable control of the Party affected, including but not limited to
acts of God, embargoes, governmental restrictions, fire, flood, explosion, riots, wars, civil disorder, rebellion or sabotage. The Party suffering such occurrence shall immediately notify the other Party as soon as practicable, and any time for
performance hereunder shall be extended by the actual time of delay caused by the occurrence. 
 11.9 Independent Contractors.
In making and performing this Agreement, InterMune and Connetics act and shall act at all times as independent contractors and nothing contained in this Agreement shall be construed or implied to create an agency, partnership or employer and
employee relationship between InterMune and Connetics. At no time shall one Party make commitments or incur any charges or expenses for or in the name of the other Party. 

11.10 Severability. If any part of this Agreement is declared invalid by any legally governing authority having jurisdiction over either
Party, then such declaration shall not affect the remainder of the Agreement and the Parties shall revise the invalidated part in a manner that will render such provision valid without impairing the Parties’ original interest. 

11.11 Cumulative Rights. The rights, powers and remedies hereunder shall be in addition to, and not in limitation of, all rights, powers
and remedies provided at law or in equity, or under any other agreement between the Parties. All of such rights, powers and remedies shall be cumulative, and may be exercised successively or cumulatively. 

11.12 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be an original and all of which
shall constitute together the same document. 
 11.13 Entire Agreement. This Agreement and any and all Exhibits referred to
herein, in conjunction with the other “Intercompany Agreements” (as defined in that certain Collaboration Agreement by and between the Parties dated April 27, 1999 excluding the “Amended and Restated Service Agreement”),
embodies the entire understanding of the Parties with respect to the subject matter hereof and of the “Intercompany Agreements,” and supersedes and terminates all previous communications, representations or understandings, either oral or
written, between the Parties relating to the subject matter hereof and of the “Intercompany Agreements.” The Amended and Restated Service Agreement is hereby terminated in its entirety, except for the provisions of the sections set forth
in Section 14 therein. 

  
 18 

 IN WITNESS WHEREOF, both InterMune and
Connetics have executed this Agreement, as of the day and year first written above. 
  

									
	INTERMUNE PHARMACEUTICALS, INC.	 		 	CONNETICS CORPORATION
					
	By:	 	/s/ S. Scott Harkonen	 		 	By:	 	Thomas G. Wiggans

									
	Print Name:	 	W. Scott Harkonen	 		 	Print Name:	 	Thomas G. Wiggans

									
	Title:	 	Pres/CEO	 		 	Title:	 	President & CEO

  
 19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]